FEB 0 8 2000

Molecular medicine today

Author Index

Subject Index

Books Reviewed

1999

Vol 5
Issues 1–12
ISSN 1357 4310

ELSEVIER
SCIENCE
LONDON

Molecular Medicine Today

Elsevier Science London,
84 Theobald's Road,
London, UK WC1X 8RR
Tel: +44 020 7611 4400
Fax: +44 020 7611 4470
E-mail: mmt@current-trends.com

Advisory Editorial Board

S. Agrawal, *Cambridge, USA*
K.Alitalo, *Helsinki, Finland*
H. Blau, *Stanford, USA*
D. Choi, *St Louis, USA*
T. Cox, *Cambridge, UK*
K. Culver, *East Hanover, USA*
K. Davies, *Oxford, UK*
I. Dunham, *Hinxton, UK*
F. Gage, *La Jolla, USA*
D. Gordon, *Manchester, UK*
W. Günzburg, *Vienna, Austria*
J.M. Leiden, *Boston, USA*
M.A. Liu, *Emeryville, USA*
K. Matsushima, *Tokyo, Japan*
A. McMichael, *Oxford, UK*
A. Papavassiliou, *Patras, Greece*
W.A. Petri, *Charlottesville, USA*
D. Rader, *Philadelphia, USA*
C. Soto, *Santiago, Chile*
Z. Ram, *Tel-Hashomer, Israel*
T. Soussi, *Paris, France*
J. Uitto, *Philadelphia, USA*
L-C. Tsui, *Toronto, Canada*
D. Young, *London, UK*

Editor **Catherine Brooksbank**

Editorial Assistants **Jane Alfred and Bea Perks**

Editorial Administrators **Alan Sloane, Anne Ward, Helen Steele and Helen Gannon**

Publishing Manager **Rob Brines**

© 2000 Elsevier Science Ltd. All rights reserved.

This journal and the individual contributions contained in it are protected by the copyright of Elsevier Science Ltd. Except as outlined in the terms and conditions, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior written permission of the publisher, Elsevier Science London, 84 Theobald's Road, London, UK WC1X 8RR

AUTHOR INDEX

Abbreviations: (B) Books; (C) Letters

A

Abraham, E. and Marshall, J.C., Sepsis and mediator-directed therapy: rethinking the target populations 56
Abramson, S.B., see Evans, C.H. 148
Acton, S.L., Kozarsky, K.F. and Rigotti, A., The HDL receptor SR-BI: a new therapeutic target for atherosclerosis? 518
Aldred, M., New light on retinal gene therapy 52
Aldred, M., Gene therapy for eye cancer? 193
Aldred, M.A., Dominant-negative isoforms modulate phenotype in inherited cardiac arrhythmias 330
Aldred, M., Menière's disease – a genetic imbalance? 464
Alfred, J., Molecular changes herald a new era for cervical cancer screening 189
Alfred, J., A new mouse model of BRCA1 breast cancer 284
Anderson, G.G. and Cookson, W.O.C.M., Recent advances in the genetics of allergy and asthma 264
Angèle, S., see Hall, J. 157
Arbibe, L., see Touqui, L. 244
Artlett, C.M., Smith, J.B. and Jimenez, S.A., New perspectives on the etiology of systemic sclerosis 74
Aviram, M., Does paraoxonase play a role in susceptibility to cardiovascular disease? 381

B

Baldwin, S.A., Mackey, J.R., Cass, C.E. and Young, J.D., Nucleoside transporters: molecular biology and implications for therapeutic development 216
Barsh, G.S., see Wilson, B.D. 250
Baylink, D.J., Strong, D.D. and Mohan, S., The diagnosis and treatment of osteoporosis: future prospects 133
Begley, C.G., see Grant, S.L. 406
Bianco, P. and Gehron Robey, P., An animal model of fibrous dysplasia 322
Bonn, D., Targeting protein breakdown to treat cancer 48
Bonn, D., Q fever vaccine on trial for type I diabetes 143
Bradley, D., Border control thwarts particles entering the brain 237
Bradley, L.A., see Burke, W. 428
Brayman, K.L., see Deng, S. 400
Brooksbank, C., Hope, not hype, for the future of stem-cell-based therapies 1
Brooksbank, C., Parasite genomes: drugs and vaccines up for grabs 11
Brooksbank, C., How much molecular medicine do medical students need to learn? (L) 100
Brooksbank, C., see Sansom, C. 235
Brooksbank, C., Genes and environment: informing future public health policy 236
Brooksbank, C., Disease models: relevance is everything 274
Brooksbank, R.A., Charting the genome 7
Brooksbank, R.A., Collagen polymorphism hits back 422
Brooksbank, R.A., Modelling Huntington's disease 285
Browman, K.E. and Crabbe, J.C., Alcohol and genetics: new animal models 310
Brown, Z., see Herlaar, E. 439
Burke, W., Franks, A.L. and Bradley, L.A., Screening for hereditary hemochromatosis: are DNA-based tests the answer? 428
Bustin, S.A., *Clinical Applications of PCR* (B) 10
Bustin, S.A., Loss of imprinting marks predisposition to colorectal cancer? 54
Bustin, S.A., GABAB receptors take their partners 99
Bustin, S.A., DNA methyltransferase and cancer: the jury's still out 465
Bustin, S.A., Dissecting the molecular basis of chemosensitivity 508

C

Canick, J.A., Kellner, L.H., Cole, L.A. and Cuckle, H.S., Urinary analyte screening: a noninvasive detection method for Down syndrome? 68
Caplen, N., *Gene Therapy: Principles and Applications* (B) 424
Caplen, N., Gene therapy under pressure 508
Caplen, N.J., Tolerating adenoviral vectors 53
Caplen, N.J., Gene transfer to liver 239
Caplen, N.J., Gene therapy for HIV infection: safe if not efficacious 375
Caskey, C.T., see Morsy, M.A. 18
Cass, C.E., see Baldwin, S.A. 216
Caulfield, T. and Hirtle, M., Regulating the genetic revolution 198
Chen, X., The p53 family: same response, different signals? 387
Coffey, A., IL-13: proving its role in asthma 99
Colaco, C.A.L.S., Why are dendritic cells central to cancer immunotherapy? 14
Cole, L.A., see Canick, J.A. 68
Cookson, W.O.C.M., see Anderson, G.G. 264
Cox, T.M., Medical education: catering for the carers as well as the innovators (L) 103
Cox, T.M., see Griffiths, W.J.H. 431
Crabbe, J.C., see Browman, K.E. 310
Cuckle, H.S., see Canick, J.A. 68
Curiel, D.T., see Reynolds, P.N. 25

D

Dawson, E., New collaborations make pharmacogenomics a SNP 280
Dawson, E., SNP maps: more markers needed? 419
Deng, S. and Brayman, K.L., Gene therapy strategies to facilitate organ transplantation 400
Domen, J. and Weissman, I.L., Self-renewal, differentiation or death: regulation and manipulation of haematopoietic stem cell fate 201
Dorrell, S., US $30 million funding boost for biomedical engineering 3
Dorrell, S., Is Tourette's syndrome one of the PANDAS? 6
Dorrell, S., Virus buster for transfusion blood 49
Dorrell, S., Blocking HIV-1 infection with intrakines 97

Dorrell, S., International grants for infectious disease research 327
Dorrell, S., Australians respond to cash crisis 328
Dorrell, S., Clues to common weight disorders from rare lipodystrophies? 328
Dorrell, S., Nanobacteria linked to kidney disease 373
Dorrell, S., NIH announces funding for structural genomics centres 418
Dorrell, S., Rare disorder may provide target for CF therapy 462
Duncan, G., see McCormick, C. 481
Dunham, I., *Bioinformatics: A Practical Guide to the Analysis of Genes and Proteins* (B) 332
Durham, N.P. and Hall, A.S., Genes and the heart: a quest for new therapeutic strategies 195

E

Elkeles, A. and Oren, M., Cancer: molecular players and unifying principles 334
Elsevier Trends Journals, Online access to *Molecular Medicine Today* 187
Evans, C.H., Rediske, J.J., Abramson, S.B. and Robbins, P.D., Joint efforts: tackling arthritis using gene therapy 148
Evans, K.L., Alcoholic mice shed light on the human condition 53
Evans, K.L., Polyglutamine expansions: mechanisms of disease 240
Evans, K.L., The complexity of simple disorders 376

F

Farza, H. and Watkins, H., Animal models for familial hypertrophic cardiomyopathy 544
Feng, M., see Reynolds, P.N. 25
Ferrone, S., see Hicklin, D.J. 178
Flock, J-I., Extracellular-matrix-binding proteins as targets for the prevention of *Staphylococcus aureus* infections 532
Fox, A.J., see Walker, K. 319
Franks, A.L., see Burke, W. 428
Fricker, J., Tackling the molecular basis of preterm birth 4
Fricker, J., Turning off RB for a healthy heart? 50
Fricker, J., Visualizing gallstone formation 96
Fricker, J., Human neural stem cells on trial for Parkinson's disease 144
Fricker, J., Ubiquitination gene defect found in DiGeorge syndrome 233
Fricker, J., A vaccine approach to healthy lipoprotein levels 281
Fricker, J., A model approach to accelerated drug discovery 325
Fricker, J., On the TRAIL to a new cancer therapy 374
Fricker, J., Removing the roadblocks to nerve regrowth 416
Fricker, J., Role of IL-13 in Hodgkin's disease 463
Fricker, J., Heart disease linked to oestrogen-receptor gene methylation 505

G

Gage, F.H., see Senut, M.C. 152
Gage, F.H., see Shihabuddin, L.S. 474
Ganz, T. and Lehrer, R.I., Antibiotic peptides from higher eukaryotes: biology and applications 292
Gehron Robey, P., see Bianco, P. 322
Giffard, R.G., see Yenari, M.A. 525
Giles, R.H., Hematological cancers: is a unifying mechanism within our grasp? 510
Gimbrone, M.A., see Topper, J.N. 40
Gowen, M., see Lazner, F. 413
Grant, S.L. and Begley, C.G., The oncostatin M signalling pathway: reversing the neoplastic phenotype? 406
Gretch, D.R., see Rosen, H.R. 393
Griffiths, W.J.H., Kelly, A.L. and Cox, T.M., Inherited disorders of iron storage and transport 431
Gu, Z., see Kwok, P-Y. 538
Guilford, P., E-cadherin downregulation in cancer: fuel on the fire? 172
Günzburg, W.H., *Xenotransplantation* (B) 377
Gurwitz, D., Sperm conceive cues in surprising ways 8
Gurwitz, D., Coronary artery disease therapy: simple as L-arginine? 98
Gurwitz, D., Oxidative neuronal RNA damage in Alzheimer's disease 194
Gurwitz, D., New leads for asthma therapy 329
Gurwitz, D., Complement depletion or blockade could save lives of sepsis victims 376
Gurwitz, D., *Marihuana and Medicine* (B) 378
Gurwitz, D., AMPA receptors: a better target for ischaemic brain damage? 464
Gwinn-Hardy, K., see Hardy, J. 514

H

Habeck, M., New hepatitis virus discovered 462
Habeck, M., Gelsolin: a new marker for breast cancer? 503
Hafezparast, M., SMN: is it the messenger or the executioner? 98
Hall, A.S., see Durham, N.P. 195
Hall, J. and Angèle, S., Radiation, DNA damage and cancer 157
Handrow-Metzmacher, H., see Starzinski-Powitz, A. 304
Hardy, J. and Gwinn-Hardy, K., Neurodegenerative disease: a different view of diagnosis 514
Herlaar, E. and Brown, Z., p38 MAPK signalling cascades in inflammatory disease 439
Hernandez, D., Nuclear inclusions in CAG repeat diseases: toxic or protective? 7
Hewson, R., Papilloma virus: tools and vectors 8
Hewson, R., Alphaviruses to the rescue? 146
Hewson, R., Nef: multi-tasker and sitting duck? 422
Hicklin, D.J., Marincola, F.M. and Ferrone, S., HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story 178
Higashi, H., see Karima, R. 123
Higgins, L.S., Animal models of Alzheimer's disease 274
Hirtle, M., see Caulfield, T. 198
Hnatowich, D.J., Changing focus: applying antisense to nuclear medicine imaging (L) 151
Hudson, P.J., see Irving, R.A. 379
Hundert, E.M., see Smith, H.C. (L) 102

I

Ikada, Y., *Tissue Engineering Methods and Protocols* (B) 333
Inui, A., Neuropeptide Y: a key molecule in anorexia and cachexia in wasting disorders? 79
Irving, R.A. and Hudson, P.J., Molecular diagnostics: the state of the art 379
Ishiguro, H., see Naruse, S. 493
Ivanov, E., Vitamin E: blocking the beginnings of atherosclerosis? 8
Ivanov, E., A tumour suppressor gene that does not play by the rules 52
Ivanov, E., Drug or poison: dosage is everything 146
Ivanov, E., Molecular mimicry implicated in heart disease 194
Ivanov, E., Cut the supply: a new treatment strategy for lysosomal storage diseases 330

J

Jimenez, S.A., see Artlett, C.M. 74
Joe, B. and Wilder, R.L., Animal models of rheumatoid arthritis 367
Jones, D.R.E., Why do *in utero* stem cell transplants sometimes fail? 288
Josenhans, C., see Suerbaum, S. 32

K

Kaelin, W.G., see Ohh, M. 257
Kaneda, Y., Saeki, Y. and Morishita, R., Gene therapy using HVJ-liposomes: the best of both worlds? 298

Karima, R., Matsumoto, S., Higashi, H. and Matsushima, K., The molecular pathogenesis of endotoxic shock and organ failure 123
Karima, R., *Molecular and Cellular Basis of Inflammation* (B) 467
Kaufman, D., A single initiating autoantigen for diabetes? 331
Kellner, L.H., see Canick, J.A. 68
Kelly, A.L., see Griffiths, W.J.H. 431
Kelsell, D.P. and Stevens, H.P., The palmoplantar keratodermas: much more than palms and soles 107
Kiewitz, C., see Tümmler, B. 351
Kitagawa, M., see Naruse, S. 493
Kmiec, E.B., Synthetic gene carriers: the future looks bright 241
Kola, I. and Pritchard, M., Animal models of Down syndrome 276
Kola, I., see Lazner, F. 413
Kotzian, S., see Starzinski-Powitz, A. 304
Kozarsky, K.F., see Acton, S.L. 518
Kraemer, K.H., see van Steeg, H. 86
Kühtreiber, W.M., see Lanza, R.P. 105
Kwok, P-Y. and Gu, Z., Single nucleotide polymorphism libraries: why and how are we building them? 538

L

Lachmann, R., *Molecular Virology* (2nd edn) (B) 55
Lanza, R.P. and Kühtreiber, W.M., Xenotransplantation and cell therapy: progress and controversy 105
Lazner, F., Gowen, M. and Kola, I., An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling 413
Lee, A., Animal models of *Helicobacter pylori* infection 500
Lehrer, R.I., see Ganz, T. 292
Leibowitz, G., see Levine, F. 165
Levin, L.A., see Schwartz, M. 470
Levine, F. and Leibowitz, G., Towards gene therapy of diabetes mellitus 165
Licinio, J., Prolo, P., McCann, S.M. and Wong, M-L., Brain iNOS: current understanding and clinical implications 225
Lindsay, J., The importance of location 54
Lindsay, J., Streptococcal invasive mechanisms and flesh-eating disease 193
Lindsay, J.A., UTI inflammation – is LPS not the key? 507
Lindsay, J.A., Viruses that turn bacteria pathogenic 329
Little, A-M. and Stern, P.L., Does HLA type predispose some individuals to cancer? 337
Lloyd, S., Huntingtin toxicity: nucleus or cytoplasm? 146

M

Mackey, J.R., see Baldwin, S.A. 216
Mariani, B.D., *PCR in Bioanalysis* (B) 147
Marincola, F.M., see Hicklin, D.J. 178
Marshall, J.C., see Abraham, E. 56
Matsumoto, S., see Karima, R. 123
Matsushima, K., see Karima, R. 123
McCann, S.M., see Licinio, J. 225
McCormick, C., Duncan, G. and Tufaro, F., New perspectives on the molecular basis of hereditary bone tumors 481
McIvor, R.S., see Verfaillie, C.M. 359
McKay, I.A., Immortalized keratinocytes: forever in blue genes? 193
McKay, I.A., Gun shots heal skin wounds 238
McKay, I.A., How new antibiotics are made and how they work 284
McKay, I.A., New hopes for antibacterial vaccines 331
McKenzie, K.E., Umbricht, C.B. and Sukumar, S., Applications of telomerase research in the fight against cancer 114
Melton, L., From DNA to drugs 468
Michie, C., Lessons from the survivors of Ebola infection 285
Michie, C., Mastitis and the macrophage: Trojan horses in breast milk 465
Mohan, S., see Baylink, D.J. 133
Morgan, R.A., Genetic strategies to inhibit HIV 454
Morishita, R., see Kaneda, Y. 298
Morsy, M.A. and Caskey, C.T., Expanded-capacity adenoviral vectors – the helper-dependent vectors 18
Murphy, A.L. and Russell, S.J., *Text Book of Gene Therapy* (B) 509

N

Naruse, S., Kitagawa, M. and Ishiguro, H., Molecular understanding of chronic pancreatitis: a perspective on the future 493
Nauseef, W. and Petrides, P.E., Peroxidases and human disease: a meeting of minds 58
Nicholson, S., The naked truth about RNA cancer vaccines 421

O

Oberhoffer, M., see Russwurm, S. (L) 286
Ohh, M. and Kaelin, W.G., The von Hippel–Lindau tumour suppressor protein: new perspectives 257
Ollmann, M.M., see Wilson, B.D. 250
Oren, M., see Elkeles, A. 334
Orme, I.M., Beyond BCG: the potential for a more effective TB vaccine 487
Osborne, L.R., Connexins link deafness and skin disorders 145
Osborne, L.R., Overactive fibroblast growth factor receptor 3 239
Osborne, L.R., Knockout mice for dummies 375
Osborne, L.R., Finding genes for missing digits 507

P

Palmer, T.D., see Shihabuddin, L.S. 474
Papavassiliou, A.G., Biochemistry versus molecular medicine: what should we be teaching our medical students? (L) 100
Peng, K-W., Strategies for targeting therapeutic gene delivery 448
Petrides, P.E., see Nauseef, W. 58
Phylactou, L.A., *Therapeutic Applications of Ribozymes* (B) 242
Pomp, D., Animal models of obesity 459
Pritchard, M., see Kola, I. 276
Prolo, P., see Licinio, J. 225

R

Ramsay, M., Cochlear development and the search for deafness genes 238
Ramsay, M., Fragile X syndrome: why tear your hair out? 421
Rediske, J.J., see Evans, C.H. 148
Reinhart, K., see Russwurm, S. (L) 286
Reynolds, P.N., Feng, M. and Curiel, D.T., Chimeric viral vectors – the best of both worlds? 25
Rigotti, A., see Acton, S.L. 518
Robbins, P.D., see Evans, C.H. 148
Rosen, H.R. and Gretch, D.R., Hepatitis C virus: current understanding and prospects for future therapies 393
Russell, S.J., see Murphy, A.L. (B) 509
Russwurm, S., Oberhoffer, M., Zipfel, P.F. and Reinhart, K., Procalcitonin – a novel biochemical marker for the mediator-directed therapy of sepsis (L) 286

S

Saeki, Y., see Kaneda, Y. 298
Sansom, C. and Brooksbank, C., Securing public access to genomic information: the race is on 235
Sansom, C., A breath of fresh air for patients with lung disease? 5
Sansom, C., Tandem mass spectrometry: the tool of choice for diagnosing inborn errors of metabolism 95
Sansom, C., Rooting out new drugs 191
Sansom, C., A step towards gene therapy for CF 279
Sansom, C., Aggregation inhibitors: hope for Huntington's? 372
Sansom, C., Genotyping HIV isolates paves the way to effective treatment regimes 417
Sansom, C., Carbohydrate based diagnostics 418
Sansom, C., Making sense of the human proteome 420

Sansom, C., Mice illuminate the pathways to lupus 504
Sapolsky, R.M., see Yenari, M.A. 525
Sata, M., see Walsh, K. 61
Schiller, J.T., Papillomavirus-like particle vaccines for cervical cancer 209
Schwartz, M., Yoles, E. and Levin, L.A., 'Axogenic' and 'somagenic' neurodegenerative diseases: definitions and therapeutic implications 470
Senior, K., DNA vaccine shows promise for malaria 2
Senior, K., Human embryonic stem cells: the future of transplantation medicine? 47
Senior, K., Ups and downs on the road to an HIV vaccine 141
Senior, K., Alzheimer's disease: finding the missing link 188
Senior, K., Are physician scientists close to extinction? 192
Senior, K., New drug makes host cell machinery unavailable to HIV 234
Senior, K., IL-6 and gp130 signalling: its role in chronic disease 283
Senior, K., Fingerprinting disease with protein chip arrays 326
Senior, K., Germline gene transfer during gene therapy: reassessing the risks 371
Senior, K., Genetic testing under fire 415
Senior, K., DMD improved by gentamicin 461
Senior, K., The complex puzzle of gene variation and essential hypertension 506
Senut, M.C. and Gage, F.H., Prenatal gene therapy: can the technical hurdles be overcome? 152
Serini, G., Loss of E-cadherin tyrosine phosphorylation in human cancers (L) 336
Sheerin, N.S., *The human complement system in health and disease* (B) 243
Shihabuddin, L.S., Palmer, T.D. and Gage, F.H., The search for neural progenitor cells: prospects for the therapy of neurodegenerative disease 474
Smith, H.C. and Hundert, E.M., Integrating molecular medicine into the medical school curriculum (L) 102
Smith, J.B., see Artlett, C.M. 74
Snider, B.J., Use it or lose it: activity modulates adult neurogenesis 240
Soto, C., Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease 343
Spinney, L., New peptides prevent brain damage 282
Stagg, A.J., Protective local cytotoxic T lymphocyte responses stimulated by mucosal vaccination 145
Starzinski-Powitz, A., Handrow-Metzmacher, H. and Kotzian, S., The putative role of cell adhesion molecules in endometriosis: can we learn from tumour metastasis? 304
Steinberg, G.K., see Yenari, M.A. 525
Stern, P.L., see Little, A-M. 337
Stevens, H.P., see Kelsell, D.P. 107
Strong, D.D., see Baylink, D.J. 133
Suerbaum, S. and Josenhans, C., Virulence factors of *Helicobacter pylori*: implications for vaccine development 32
Sukumar, S., see McKenzie, K.E. 114

T

Taub, R.A., In Orvieto: new insights into liver biology and disease therapy 425
Topper, J.N. and Gimbrone, M.A., Blood flow and vascular gene expression: fluid shear stress as a modulator of endothelial phenotype 40
Touqui, L. and Arbibe, L., A role for phospholipase A2 in ARDS pathogenesis 244
Trent, R.J., *Principles of molecular medicine* (B) 9
Trounson, A., *Human Cloning* (B) 423
Tufaro, F., see McCormick, C. 481
Tümmler, B. and Kiewitz, C., Cystic fibrosis: an inherited susceptibility to bacterial respiratory infections 351

U

Umbricht, C.B., see McKenzie, K.E. 114
Urban, L.A., see Walker, K. 319

V

van Steeg, H. and Kraemer, K.H., Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer 86
Verfaillie, C.M., McIvor, R.S. and Zhao, R.C.H., Gene therapy for chronic myelogenous leukemia 359

W

Walker, K., Fox, A.J. and Urban, L.A., Animal models for pain research 319
Walsh, K. and Sata, M., Is extravasation a Fas-regulated process? 61
Watkins, H., see Farza, H. 544
Weissman, I.L., see Domen, J. 201
Wilder, R.L., see Joe, B. 367
Wilson, B.D., Ollmann, M.M. and Barsh, G.S., The role of agouti-related protein in regulating body weight 250
Witherden, A., Cytokine crosstalk in the CNS: a new mechanism of neurodegeneration 466
Wong, M-L., see Licinio, J. 225

Y

Yenari, M.A., Giffard, R.G., Sapolsky, R.M. and Steinberg, G.K., The neuroprotective potential of heat shock protein 70 (HSP70) 525
Yoles, E., see Schwartz, M. 470
Young, J.D., see Baldwin, S.A. 216

Z

Zhang, S., Self-assembly of peptides in medicine: two sides of the coin 512
Zhao, R.C.H., see Verfaillie, C.M. 359
Zipfel, P.F., see Russwurm, S. (L) 286

SUBJECT INDEX

Compiled by Liza Weinkove
Abbreviations: (B), Books; (C), Letters; (D), Disease models; (E), Editorial; (L), Literature; (M), Meetings; (N), News; (O), Opinion

A
α-galactosidase A inhibitor
  in Fabry disease (L) 146
acanthosis nigricans
  FGFR3 mutations causing (L) 239
acrosome reaction
  initiation by hormones and neurotransmitters (L) 8
actin cytoskeleton
  gelsolin interaction (N) 503
acute phase response
  antimicrobial peptides 292
acute respiratory distress syndrome, ARDS
  role of phospholipase A_2 (O) 244
adeno-associated virus, AAV
  chimeric vectors 25
adenosine
  and nucleoside transporters 216
adenosine deaminase, ADA, deficiency
  prenatal gene therapy (O) 152
adenoviral vectors
  CFTR gene delivery (N) 279
  chimeric 25
  encapsidated adenovirus mini-chromosomes (L) 52
  in gene therapy 18
  helper-dependent 18
  targeted gene delivery 448
  T-cell tolerance (L) 53
adhesins
  Helicobacter pylori 32
adhesion
  cell *see* cell adhesion
adipose tissues
  inherited disorders (N) 328
African Americans
  essential hypertension and gene variations (N) 506
aging
  bone loss rates 133
  brain iNOS expression 225
agouti gene
  in hair color determination 250
agouti-related protein
  in body weight regulation 250, 336
AIDS *see also* HIV
  -related dementia, brain iNOS expression 225
  vaccine (N),(N) 97, 141
  wasting disease 79
alcohol
  in chronic pancreatitis 493
  -induced brain damage, peptides preventing (N) 282
alcoholism
  genetics 310
  molecular aspects (L) 53
allergy
  genetics 264
alphaviruses
  as viral vectors (L) 146
alveolar macrophages
  in ARDS pathogenesis (O) 244
Alzheimer's disease
  amyloid inhibitors 343
  animal models (D) 274
  brain iNOS expression 225
  genetic testing (N) 415
  overlapping pathologies/etiologies (O) 514
  oxidative neuronal RNA damage (L) 194
  presenilin 1 function (N) 188
AMPA receptors
  in ischemic brain damage (L) 464
amyloid
  inhibitors, in Alzheimer's disease 343
  mechanisms of formation (M) 512
amyloid β protein, A β
  protein chip-based assay (N) 326
  as therapeutic target 343
amyloid precursor protein, APP
  as therapeutic target 343
anchored re-sequencing approach
  in SNP library construction 538
angiogenesis
  regulation by pVHL 257
  role of leukocyte extravasation (O) 61
angiotensin II type 1 receptor antisense gene therapy
  in hypertension (L) 508
animal models *see also* knockout mice; transgenic mice
alcoholism 310
Alzheimer's disease (D) 274
asthma and allergy 264
  Down syndrome (D) 276
  familial hypertrophic cardiomyopathy (D) 544
  fibrous dysplasia (D) 322
  Helicobacter infection (D) 500
  hereditary breast cancer (L) 284
  Huntington's disease (L) 285
  new section (D) 274
  nucleotide excision repair, NER, defects 86
  obesity (D) 459
  in pain research (D) 319
  pycnodysostosis (D) 413
  rheumatoid arthritis (D) 367
  systemic lupus erythematosus (N) 504
ankylosing spondylitis
  HLA association (O) 337
anorexia
  role of neuropeptide Y 79
antibiotics
  in cystic fibrosis airway infections 351
  engineering new (L) 284
  peptides, from higher eukaryotes 292
  resistance, in wild rodents (L) 466
antibodies
  diagnostic use (M) 379
  intracellular, intrabodies, in HIV infection 454
anti-inflammatory agents
  in sepsis (M) 56
antisense strategies
  in chronic myelogenous leukemia 359
  HIV inhibition 454
  in hypertension (L) 508
  in nuclear medicine imaging (C) 151
anti-viral drugs
  resistance (N) 417
AP-1
  induction by Nef (L) 422
Apo2 ligand, Apo2L
  anti-cancer activity (N) 374
apolipoprotein E, apoE
  -deficient mice, atherosclerosis (L) 8
apoptosis
  cancer therapy inducing (N) 374
  Fas-mediated, in vascular endothelium (O) 61
  hematopoietic stem cells *in vitro* 201
  inhibition, in diabetes 165
  p53 family proteins and 387
  proteasome inhibitor-induced (N) 48
  SMN protein and (L) 98

L-arginine
in coronary artery disease (L) 98
arsenic trioxide
in acute promyelocytic leukemia (M) 510
arthritis *see also* rheumatoid arthritis
erosive, animal models (D) 367
gene therapy (M) 148
aspartyl protease
presenilin 1 (N) 188
asthma
genetics 264
interleukin 13 in (L) 99
mechanisms of airway relaxation (L) 329
ataxia telangiectasia
radiation sensitivity 157
atherosclerosis
gene therapy 518
hemodynamic mechanisms 40
oestrogen-receptor gene methylation and (N) 505
paraoxonase and (O) 381
role of leukocyte extravasation (O) 61
SR-BI high-density lipoprotein receptors and 518
vitamin E and formation (L) 8
ATM gene product
radiation sensitive cancer and 157
atopy
genetic factors 264
Australia
extra research funding (N) 328
autoimmunity
in insulin-dependent diabetes (N),(L) 143, 331
in systemic lupus erythematosus (N) 504
in systemic sclerosis 74
in Tourette's syndrome (N) 6
auxotrophic BCG vaccines 487
axogenic neurodegeneration (O) 470

B

β_2-adrenergic receptor gene polymorphisms
in asthma 264
β-adrenergic receptors
and heart disease (M) 195
β-cells, pancreatic *see* pancreatic β-cells
β core fragment, βCF
urinary, prenatal screening for Down syndrome 68
β-sheet breaker peptides 343
bacille Calmette–Guérin, BCG, vaccine
comparative genomics (L) 331
future strategies 487
bacterial respiratory infections
in cystic fibrosis 351
bacteriophages
in diagnostics (M) 379
virulence genes (L) 329
BCR–ABL fusion gene
therapies targeting 359
bioanalysis
PCR in (B) 147
biochemistry
in medical school curriculum (C) 100
bioinformatics (B) 332
biomedical engineering
funding for (N) 3
biotechnology
regulatory approaches (O) 198
blood–brain barrier
second barrier distal to (N) 237
blood flow
vascular gene expression and 40
blood products
destruction of viruses (N) 49
bone
density, peak, genetic influences 133
fibrous dysplasia, animal models (D) 322
loss rates in elderly 133
remodeling, cathepsin K and (D) 413
tumors, hereditary 481
brain
amyloid, inhibitors 343
damage, peptides preventing (N) 282
inducible nitric oxide synthase, iNOS 225
ischemia *see* cerebral ischemia
second barrier to entry of particles (N) 237
Brca1 mutant mice (L) 284
breast cancer
ATM gene mutations 157
carbohydrate-based diagnostics (N) 418
gelsolin as marker (N) 503
hereditary, mouse model (L) 284
oncostatin M and 406
breast milk
HIV infectivity of (L) 465
Brugia malayi
genome sequencing (M) 11
Burkholderia cepacia infections
in cystic fibrosis 351
N-butyldeoxynojirimycin
in Sandhoff disease (L) 330
bystander effect
in gene therapy of retinoblastoma (L) 193

C

cachexia
role of neuropeptide Y 79
CagA, cytotoxin-associated gene A
Helicobacter pylori 32
CAG repeat diseases
pathogenic role of nuclear inclusions (L),(L),(L) 7, 146, 240
calcitonin, salmon
in osteoporosis 133
cancer *see also* tumors
cachexia, role of neuropeptide Y 79
chemotherapy *see* chemotherapy
DNA methyltransferase and (L) 465
E-cadherin downregulation in (C) 172, 336
gene therapy (B) 424
HLA associations (O) 337
HLA class I downregulation 178
HVJ-liposome gene delivery 298
immunotherapy
dendritic cell-based (O) 14
HLA class I downregulation and 178
molecular basis (M) 334
new therapy (N) 374
oncostatin M effects 406
and palmoplantar keratoderma 107
proteasome inhibitor therapy (N) 48
radiation-sensitive 157
ribozyme-mediated inhibition (B) 242
telomerase and 114
vaccine, RNA (L) 421
VHL gene and 257
candidate-gene mapping
in SNP library construction 538
cannabinoids (B) 378
carbohydrate-based diagnostics (N) 418
cardiac arrhythmias
inherited, phenotypic modulation (L) 330
cardiac development
genetic factors (M) 195
cardiac myocytes
IL-6 and gp130 signaling (N) 283
negative regulation of cell cycle (N) 50
cardiology
molecular (B) 9
cardiomyopathy, familial hypertrophic
animal models (D) 544
cardiotrophin (N) 283
cardiovascular disease *see also* coronary artery disease; heart disease; hypertension
genomics (M) 195
nucleoside transporters and 216
paraoxonase and (O) 381
SR-BI high-density lipoprotein receptors and 518
cartilage
gene therapy targeted to (M) 148
caspases
heat shock protein 70 and 525
catenins
E-cadherin interactions 172
cathepsin K
knockout mice (D) 413
as therapeutic target, in osteoporosis 133
CCR-5 chemokine co-receptor
inactivation by intrakines (N) 97
CD14
in lipopolysaccharide signaling 123
Cdc6
cervical cancer diagnosis (N) 189
Cdc53
similarity to cullin 2 257
CDH1 gene mutations
cancer predisposition 172

celiac disease
HLA association (O) 337
cell adhesion
E-cadherin-mediated (C) 172, 336
molecules, in endometriosis 304
cell cycle
negative regulation in cardiac myocytes (N) 50
p53 family proteins 387
regulation by pVHL 257
cell therapy *see also* stem cells
neurodegenerative diseases 474
and xenotransplantation (M) 105
central nervous system, CNS *see also* brain; neurodegenerative diseases
cytokine crosstalk (L) 466
stem cells *see* neural progenitor, stem cells
cerebral ischemia
AMPA receptor blockade (L) 464
brain iNOS expression 225
heat shock protein 70 expression 525
cervical cancer
papillomavirus-like particle vaccines 209
screening (N) 189
CFTR gene
delivery methods (N) 279
mutations
in chronic pancreatitis 493
respiratory infections and 351
chemokines
intracellular, blocking HIV infection (N) 97
in multiple organ failure 123
chemotherapy
nucleoside transporters and 216
p53 and sensitivity to (L) 508
recent studies (M) 334
chimeric viral vectors 25
Chlamydia infections
and heart disease (L) 194
cholecystokinin
modulation of appetite 79
cholesterol
in gallstone formation (N) 96
cholesteryl ester transfer protein, CETP
vaccine (N) 281
chromosome 22q11 deletion syndrome (N) 233
chronic obstructive pulmonary disease, COPD
novel $P2Y_2$ receptor agonist therapy (N) 5
citrullinemia, bovine model
gene therapy (L) 239
Clinical Genetics Network, CGN (N) 280
cloning, human
ethics (B) 423
regulatory responses (O) 198
COCH gene
in Menière's disease (L) 464
Cockayne syndrome
defective DNA repair 86
coeliac disease *see* celiac disease
collagen
IX polymorphisms (L) 422
binding proteins, staphylococcal 532
colorectal cancer
DNA methylation (L) 465
risk, loss of imprinting and (L) 54
complement
depletion/blockade in sepsis (L) 376
in health and disease (B) 243
computing
and bioinformatics (B) 332
concentrative nucleoside transporters, CNTs 216
congenital malformations
chromosomal deletion map (L) 7
connexins
in deafness and skin disorders (L) 145
coronary artery disease *see also* heart disease
estrogen receptor gene methylation and (N) 505
genetic factors (M) 195
L-arginine therapy (L) 98
paraoxonase polymorphisms and (O) 381
corticotropin-releasing factor, CRF
modulation of appetite 79
corticotropin-releasing hormone, CRH
in preterm birth (N) 4
cottontail rabbit papillomavirus, CRPV
VLP vaccination 210
cre–lox system
generation of helper-dependent vectors 18
CTLA4Ig gene transfer
prevention of graft rejection 400
cullin 2, Cul-2
pVHL interactions 257
CXCR-4 chemokine co-receptor
inactivation by intrakines (N) 97
cyclic AMP, cAMP
in ARDS pathogenesis (O) 244
cyclin D1
in breast cancer (N) 503
cyclooxygenase-2, COX-2
in ischemic brain damage (L) 464
cystic fibrosis, CF
antimicrobial peptide inactivation 292
gene therapy (N) 279
meconium ileus (L) 376
novel $P2Y_2$ receptor agonist therapy (N) 5
pancreatic insufficiency 493
prenatal gene therapy (O) 152
respiratory infections 351
sodium transport defect (N) 462
cystic fibrosis transmembrane conductance regulator gene *see CFTR* gene
cytokines *see also* specific cytokines
in anorexia and cachexia 79
crosstalk in CNS (L) 466
in endotoxic shock 123
gene transfer, in organ transplantation 400
in liver regeneration (M) 425
receptors 406
cytotoxic T lymphocytes, CTLs
in Ebola infection (L) 285
generation of tumor-specific (O) 14
mucosal vaccination stimulating (L) 145
tumor cell recognition 178

D

dactylaplasia, Dac, mutant mice (L) 507
Dactylin gene (L) 507
deafness
candidate genes (L) 238
connexin defects (L) 145
in Menière's disease (L) 464
and palmoplantar keratoderma 107
death receptors (N) 374
defensins 292
dementia *see also* Alzheimer's disease; neurodegenerative diseases
AIDS-related, brain iNOS expression 225
dendritic cells
cancer immunotherapy based on (O) 14
dentate granule cells
heat shock protein 70 expression 525
1-deoxy-galactonojirimycin, DGJ
in Fabry disease (L) 146
desmosomal proteins
in palmoplantar keratodermas 107
dHAND transcription factor (N) 233
DHFR gene therapy
in chronic myelogenous leukemia 359
diabetes mellitus
gene therapy 165
type 1, insulin-dependent, IDDM
HLA association (O) 337
initiating autoantigen (L) 331
vaccine preventing onset (N) 143
diabetic retinopathy
treatment (L) 466
diagnostic technology *see* molecular diagnostics
diet
paraoxonase activity and (O) 381
differentiation
hematopoietic stem cells 201
human embryonic stem cells (E),(N) 1, 47
DiGeorge syndrome
ubiquitin fusion degradation 1, UFD1, gene defect 233
dipalmitoyl phosphatidylcholine, DPPC
hydrolysis by phospholipase A_2 (O) 244
disseminated intravascular coagulation, DIC
multiple organ failure and 123

DNA
-based diagnostics (M) 379
mismatch repair, MMR, chemosensitivity and (L) 508
radiation-induced damage 157
repair of UV-induced damage 86
sequence data
bioinformatics (B) 332
public access (N) 235
vaccines
for malaria (N),(M) 2, 468
topically applied (L) 466
tuberculosis 487
DNA methyltransferase
and cancer (L) 465
Dnmt-1
tumor suppressor gene downregulation (L) 465
dominant-negative effects
in *KCNQ1* mutations (L) 330
dopamine D_2 receptors, DRD2
in alcoholism (L) 53
Down syndrome
animal models (D) 276
noninvasive prenatal screening 68
Drosophila melanogaster
alcohol-related studies 310
drug discovery
accelerated (N) 325
DNA-based strategies (M) 468
drug resistance gene therapy
in chronic myelogenous leukemia 359
Duchenne muscular dystrophy (N) 461

E

Ebola virus
survivors of infection (L) 285
E-cadherin
downregulation in cancer (C) 172, 336
in endometriosis 304
economics
xenotransplantation (B) 377
eicosanoids
in inflammation (B) 467
elongins B and C
pVHL interactions 257
embryonic stem cells
human (E),(N),(M) 1, 47, 105
encapsidated adenovirus mini-chromosome, EAM, vectors (L) 52
endocarditis
staphylococcal 532
endogenous genomic insertions (N) 371
endometriosis
cell adhesion molecules in 304
endothelium, vascular *see* vascular endothelium
endotoxic shock
molecular pathogenesis 123
endotoxin, lipopolysaccharide, LPS
inducing brain iNOS expression 225
in polycystic kidney disease (N) 373
signaling pathway 123
as therapeutic target, in sepsis (M) 56, 123
in urinary tract infections, UTI (L) 507
end-replication problem 114
environment
enriched, enhancing adult neurogenesis (L) 240
factors in asthma and allergy 264
Environmental Genome Project (N) 236
eosinophil peroxidase, EPO (M) 58
Epstein–Barr virus, EBV
coupled with HVJ-liposomes 298
equilibrative nucleoside transporters, ENTs 216
Escherichia coli
urinary tract infections (L) 507
estriol, urinary, uE3
prenatal screening for Down syndrome 68
estrogen receptor genes
methylation, and heart disease (N) 505
ethanol *see* alcohol
ethics
genetic research (O) 198
genetic testing (N) 415
human cloning (B) 423
human embryonic stem cells (N) 47
prenatal gene therapy (O) 152
eukaryotes
antimicrobial peptides from 292
exostoses
hereditary multiple, HME 481
expressed sequence tags, ESTs
in genome mapping (L) 7
human cochlea (L) 238
in SNP library construction 538
EXT1/EXT2 genes 481
extracellular matrix
artificial (B) 333
binding proteins, ECMBPs, staphylococcal vaccines based on 532
interactions in endometriosis 304
regulation by pVHL 257

F

Fabry disease
α-galactosidase A inhibitor (L) 146
familial hypertrophic cardiomyopathy
animal models (D) 544
Fas ligand
inducing tolerance to adenoviral vectors (L) 53
potential therapeutic use (O) 61
regulation of leukocyte extravasation (O) 61
ferritin 431
fetal alcohol syndrome, FAS
prevention (N) 282
fetal cells
microchimerism, in systemic sclerosis 74
fetus
gene transfer (O) 152
stem cell transplants (O) 288
fibroblast growth factor receptor 3, FGFR3
mutations, causing short stature (L), (C) 239, 336
fibroblasts
cancer associated, CAFs (M) 334
fibronectin
binding proteins, staphylococcal 532
pVHL interaction 257
fibrous dysplasia
animal models (D) 322
fluid shear stress
modulating endothelial phenotype 40
fluorescence assay
gallstone formation (N) 96
FMR1 mutations
hair root analysis (L) 421
Food and Drug Administration, FDA
on germline gene transfer (N) 371
fragile X syndrome
hair root analysis (L) 421
funding
extra research, in Australia (N) 328
infectious diseases research (N) 327
structural genomics (N) 418
fusion proteins
in leukemia (M) 510

G

γ-aminobutyric acid, GABA
actions on human sperm (L) 8
B receptors
in alcoholism 310
heteromeric complexes (L) 99
gallstone formation (N) 96
gangliosides
complex, knockout mice (N) 416
gastric cancer
in *Helicobacter* infection in animals (D) 500
hereditary diffuse 172
gastric ulcers
in *Helicobacter* infection in animals (D) 500
gelsolin
in breast cancer (N) 503
gene–environment interactions (N) 236
in asthma and allergy 264
gene expression
alcohol-induced changes 310
immortalized keratinocytes (L) 193
targeted 448
vascular, blood flow and 40
gene guns
PDGF transfer to skin wounds (L) 238
gene marking (B) 424
gene targeting vectors
for knockout mouse generation (L) 375
recent strategies 448
gene therapy
antisense *see* antisense strategies
arthritis (M) 148
atherosclerosis 518
chimeric viral vectors 25

chronic myelogenous leukemia 359
cystic fibrosis (N) 279
diabetes mellitus 165
germline gene transfer (N) 371
helper-dependent vectors 18
hepatic (M) 425
HIV infection (L) 375, 454
HVJ-liposomes 298
liver-targeted (L) 239
long-term gene expression (L) 193
neurodegenerative diseases 474
osteoporosis 133
prenatal (O) 152
to prevent graft rejection 400
principles and applications (B) 424
retinitis pigmentosa model (L) 52
retinoblastoma (L) 193
synthetic gene carriers (M) 241
targeting strategies 448
textbook (B) 509
genetic disorders
complexity of simple (L) 376
gene therapy (B) 424
genetic map
human (L) 7
genetic risk assessment
osteoporosis 133
genetics
alcoholism 310
asthma and allergy 264
molecular (B) 9
regulatory approaches (O) 198
split-hand/split-foot malformation (L) 507
systemic lupus erythematosus (N) 504
genetic testing
Alzheimer's disease (N) 415
hereditary hemochromatosis (O) 428
genodermatoses
palmoplantar keratodermas 107
genome-wide mapping
single nucleotide polymorphisms (N) 419, 538
genomic insertions
endogenous (N) 371
genomics
BCG vaccines (L) 331
cardiovascular disease (M) 195
protozoan and helminth parasites (M) 11
public access to data (N) 235
structural, funding (N) 418
genomic stability
in cancer (M) 334
genotyping
HIV (N) 417
single nucleotide polymorphisms 538
gentamicin
in Duchenne muscular dystrophy (N) 461
germline gene transfer
inadvertent (N) 371
glaucoma
axogenic neuronal degeneration (O) 470
glucose-6-phosphate dehydrogenase, G6PDH
candidate anti-HIV drug inhibiting (N) 234
glutamate
in ischemic brain damage (L) 464
in neurodegenerative disorders (O) 470
glutamate decarboxylase, GAD
in initiation of diabetes (L) 331
glycoproteins
in diagnostics (N) 418
gp130 signaling
in chronic disease (N) 283
oncostatin M and 406
graft rejection
gene therapy to prevent 400
graft-versus-host disease
similarity to systemic sclerosis 74
Guillain–Barré syndrome (N) 416

H

hair color
genetic regulation 250
hair root analysis
in fragile X syndrome (L) 421
haploinsufficiency
of *UFD1* in DiGeorge syndrome (N) 233
of $p27^{Kip1}$ (L) 52
HE2000
candidate anti-HIV drug (N) 234
health insurance
genetic testing and (N) 415
hearing loss *see* deafness
heart disease *see also* coronary artery disease
genomics (M) 195
HVJ-liposome gene delivery 298
molecular mimicry (L) 194
heart failure
and palmoplantar keratoderma 107
heat shock proteins
70 kDa, HSP70, neuroprotective potential 525
Helicobacter pylori 32
in tumor immunology (O) 14
hedgehog proteins 481
Helicobacter pylori
animal models of infection (D) 500
vaccine development 32
virulence factors 32
helminth parasites
genomes (M) 11
helper-dependent adenoviral vectors 18
hemagglutinating virus of Japan, HVJ
combined with liposomes 298
hematological malignancies *see also* leukemia
unifying mechanism (M) 510
hematopoietic stem cells, HSCs
in chronic myelogenous leukemia 359
engineered, in transplant tolerance induction 400
in HIV gene therapy (L) 375, 454
in utero transplantation (O) 288
manipulation of fate 201
hemochromatosis, hereditary 431
screening for (O) 428
hemoglobinopathies
in utero stem cell transplantation (O) 288
hemophilia B mice
gene therapy (L) 239
heparan sulfate proteoglycans
in bone development 481
hepatic nuclear factors, HNFs (M) 425
hepatitis
hepatitis C virus, HCV 393
new virus (N) 462
viral (M) 425
hephaestin 431
hereditary diffuse gastric cancer, HDGC, syndrome 172
hereditary multiple exostoses, HME 481
herpes simplex virus, HSV
chimeric vectors 25
HFE gene 431
screening for mutations (O) 428
high density lipoprotein, HDL
metabolism and antiatherogenic properties 518
paraoxonase interactions (O) 381
receptor, scavenger receptor class B, type I, SR-BI 518
vaccine approach to increasing (N) 281
histamine
modulation of appetite 79
HIV *see also* AIDS
in breast milk (L) 465
genetic inhibition 454
genotyping (N) 417
infection
gene therapy (L) 375, 454
intrakines blocking (N) 97
Nef functions (L) 422
neutralizing antibodies (N) 141
new drug candidate, HE2000 (N) 234
vaccine (N),(N) 97, 141
HLA class I
downregulation in human cancers 178
HLA class II
in systemic sclerosis pathogenesis 74
HLA haplotypes
in asthma and atopy 264
cancer associations (O) 337
hMRE11–hRAD50 protein complex
in radiation-induced DNA damage 157
Hodgkin's disease
interleukin-13 function (N) 463
Hop proteins
Helicobacter pylori 32
Hox genes
hematopoietic stem cell fate and 201

human chorionic gonadotropin, hCG
prenatal screening for Down syndrome 68
human cloning *see* cloning, human
human embryonic stem cells (E),(N),(M) 1, 47, 105
human genome project
in SNP library construction 538
human immunodeficiency virus *see* HIV
human leukocyte antigens *see* HLA
human papillomaviruses, HPV
in cervical cancer 209
virus-like particles *see* virus-like particles
Human Proteomics Initiative (N) 420
human telomerase reverse transcriptase, hTERT 114
human telomerase RNA, hTR 114
huntingtin
aggregation inhibitors (N) 372
Huntington's disease
animal models (L) 285
non-neuronal nuclear inclusions (L) 285
pathogenic role of nuclear inclusions (L),(L) 7, 146
therapeutic strategies (N) 372
Hutterites
asthma susceptibility loci 264
HVJ-liposomes
gene therapy using 298
20-hydroxyeicosatetraenoic acid
in airway relaxation (L) 329
hyperacute rejection
xenogeneic transplants (M) 105
hypertension
angiotensin II type 1 receptor antisense gene therapy (L) 508
essential, gene variations and (N) 506
hypertrophic cardiomyopathy, familial
animal models (D) 544
hypothalamus
agouti-related protein function 250
in anorexia and cachexia 79

I

IgE receptor, high-affinity, FcεRI variants and atopy risk 264
immortalized keratinocytes
long-term transgene expression (L) 193
immune surveillance, tumors
evasion (O) 14
HLA associations and (O) 337
immunogenicity
adenoviral vectors (L) 53
HVJ-liposomes 298
immunotherapy
cancer *see* cancer, immunotherapy
imprinting
loss of, LOI, colorectal cancer risk and (L) 54
Inactine
destruction of viruses in blood products (N) 49
inborn errors of metabolism
diagnosis by tandem mass spectrometry (N) 95
Indian hedgehog
in bone development 481
infections *see also* sepsis
respiratory, in cystic fibrosis 351
xenotransplantation risks (B) 377
infectious diseases
research grants (N) 327
inflammation
increased brain iNOS expression 226
molecular and cellular basis (B) 467
p38 MAPK signaling cascades 439
infrared spectroscopy
in cervical cancer screening (N) 189
INS365, novel $P2Y_2$ receptor agonist
in lung disease (N) 5
insulin-like growth factor, IGF-I
TNF-α interaction in CNS (L) 466
integration
chimeric viral vectors 25
integrins
in endometriosis 304
p38 MAPK-mediated upregulation 439
interferon-α, IFN-α
in hepatitis C 393
interleukin 1, IL-1
inhibition in sepsis (M) 56
interleukin 1β, IL-1β
inducing iNOS expression 225
interleukin 4, IL-4
in asthma (L) 99
receptor, mutations in atopy 264
interleukin 6, IL-6
in chronic disease (N) 283
family of cytokines 406
interleukin 10, IL-10
gene therapy in arthritis (M) 148
polymorphisms, in atopy and asthma 264
interleukin 12, IL-12
mucosal vaccination with (L) 145
interleukin 13, IL-13
in asthma (L) 99
in Hodgkin's disease (N) 463
intervertebral disc disease
collagen IX polymorphisms (L) 422
intracellular antibodies, intrabodies
in HIV infection 454
intrakines
blocking HIV infection (N) 97
in utero transplantation
stem cells (O) 288
invertebrates
antimicrobial peptides 292
ion channels
in chronic pancreatitis 493
iron
overload, in hereditary hemochromatosis (O) 428
oxide particles, barrier to entry to brain (N) 237
storage and transport, inherited disorders 431
ischemia, cerebral *see* cerebral ischemia
isoprostanes, IsoPs
in apoE-deficient mice (L) 8
in inflammation (B) 467

J

JAK–STAT pathway
oncostatin M signaling 406
Jervell and Lange–Nielsen syndrome, JLN
dominant-negative effects (L) 330
joints
gene therapy targeted to (M) 148

K

kallikrein gene variations
and essential hypertension (N) 431
KCNQ1 mutations
dominant-negative effects (L) 330
keratinocytes
long-term transgene expression (L) 193
keratins
in palmoplantar keratodermas 107
keratodermas
palmoplantar *see* palmoplantar keratodermas
kidney disease
polycystic, nanobacteria in (N) 373
killer inhibitory receptors, KIR
in tumor cell recognition 178
knockout mice
alcoholism studies 310
cathepsin K (D) 413
complex gangliosides (N) 416
dopamine D_2 receptor (L) 53
heart-specific conditional (N) 50
vector libraries (L) 375

L

lactoperoxidase, LPO (M) 58
lasers
three-dimensional tissue patterning (N) 144
learning
enhancing neurogenesis in adults (L) 240
legislation
genetic (O) 198
Leishmania
genome sequencing (M) 11
nucleoside transport 216
leptin
anorexia and cachexia and 79
downstream mediators of action 250
helper-dependent adenoviral vector 18
lethal yellow mouse 250
leukemia
acute promyelocytic, APL (M) 510
chronic myelogenous, gene therapy 359
fusion proteins (M) 510

survival rates (M) 510
T-cell prolymphocytic, T-PLL 157
unifying mechanism (M) 510
leukocytes
in multiple organ failure 123
recruitment, p38 MAPKs in 439
regulation of extravasation (O) 61
Lewy bodies (O) 514
linkage disequilibrium mapping (N) 419, 538
linkage studies
asthma and atopy 264
lipid peroxides
paraoxonase actions (O) 381
lipodystrophies
future research (N) 328
lipopolysaccharide *see* endotoxin
liposomes
cationic, *CFTR* gene delivery (N) 279
hybrid, HVJ-liposomes 298
lipoxins, LXs
in inflammation (B) 467
liver
biology and disease therapy (M) 425
chronic disease, IL-6 and gp130 signaling (N) 283
fetal, targeting hematopoietic stem cells to (O) 288
gene therapy targeted to (L) 239
regeneration (M) 425
loss of imprinting, LOI
colorectal cancer risk and (L) 54
low density lipoproteins, LDLs
paraoxonase interactions (O) 381
lupus erythematosus, systemic, SLE
genetic factors (N) 504
lysosomal storage diseases
new treatment strategy (L) 330

M

M1 protein
group A streptococci (L) 193
McCune–Albright syndrome
animal models (D) 322
Mcm5
for cervical cancer diagnosis (N) 189
macrophages
HIV-infected, in breast milk (L) 465
macrophages, alveolar
in ARDS pathogenesis (O) 244
magainins 292
major histocompatibility complex, MHC *see also* HLA
donor genes, in transplant tolerance induction 404
malaria *see also Plasmodium falciparum*
DNA vaccine (N),(M) 2, 468
mammalian artificial chromosomes, MACs (M) 241
MAPK signaling cascades
in inflammatory disease 439
marihuana
in medicine (B) 378
mastitis
HIV-infectivity of breast milk and (L) 465
matrix metalloproteinases, MMPs
as gene targets 448
meconium ileus
genetic modifiers (L) 376
medical school curriculum
molecular medicine in (C) 100, 102, 103
melanocortin receptors
in body weight regulation 250
α-melanocyte stimulating hormone, α-MSH
in hair color determination 250
memory T cells
BCG immunization 481
Menière's disease
genetic factors (L) 464
menopause, age at
genetic influences 133
methylation of estrogen receptor genes
heart disease and (N) 505
microbial surface components recognizing adhesive matrix molecules, MSCRAMMs 532
microchimerism, fetal cell
in etiology of systemic sclerosis 74
microsatellite instability
in colorectal cancer (L) 54
Miyoshi myopathy (L) 376
molecular diagnostics
advances (M) 379
carbohydrate-based (N) 418
cervical cancer (N) 189
fragile X syndrome (L) 421
hepatitis C virus 393
new hepatitis virus (N) 462
polymerase chain reaction (B) 10, 147
telomerase activity in cancer 114
molecular medicine
in medical school curriculum (C) 100, 102, 103
textbook (B) 9
molecular mimicry
in heart disease (L) 194
molecular virology (B) 55
monoclonal antibodies (M) 379
mRNA translation state
measurement (L) 466
Mucin 1, MUC1
immune non-responsiveness (O) 14
mucociliary clearance
$P2Y_2$ receptor agonist promoting (N) 5
mucosal immunity
HPV VLP vaccines inducing 210
local CTLs mediating (L) 145
multiple organ failure/dysfunction syndrome, MOF/MODS
molecular pathogenesis 123
multiple sclerosis
brain iNOS expression 225
complex gangliosides and (N) 416
muscle-restricted RB-binding protein, MRP1
cell cycle regulation (N) 50
muscular dystrophy
Duchenne (N) 461
limb girdle, 2B (L) 376
Myc
reversible tumorigenesis by (L) 466
mycobacteria, recombinant
tuberculosis vaccines 487
myelin-associated glycoprotein (N) 416
myeloperoxidase, MPO (M) 58

N

nanobacteria
in polycystic kidney disease (N) 373
National Health and Medical Research Council, NHMRC
Australian, extra funding (N) 328
National Institute of General Medical Sciences, NIGMS
structural genomics funding (N) 418
natural killer, NK, cells
tumor cell recognition 178
NBS1 gene product
radiation sensitive cancer and 157
necrotizing fasciitis
streptococcal invasive mechanisms (L) 193
Nef proteins
functions (L) 422
neonatal screening
using tandem mass spectrometry (N) 95
neural progenitor, cells 474
human, transplant studies (N) 144
neurodegenerative diseases *see also* Alzheimer's disease; Huntington's disease; Parkinson's disease
axogenic and somagenic (O) 470
cytokine crosstalk (L) 466
pathogenic mechanisms (O) 514
treatment strategies 474
neurofibrillary tangles (O) 514
neurogenesis
adult, effects of activity (L) 240
neuropeptide Y, NPY
agouti-related protein and 250
in alcoholism (L) 53
in anorexia and cachexia in wasting disorders 79
neuroprotection
heat shock protein 70 in 525
in neurodegenerative disorders (O) 470
NF-κB
gene therapy targeting 400
Nijmegen breakage syndrome
radiation sensitivity 157
nitric oxide, NO
in brain 225
in coronary artery disease (L) 98
in endotoxic shock 123
nitric oxide synthase, NOS
endothelial, eNOS, flow-regulated expression 40
inducible, iNOS, brain expression 225

nitrobenzylthioinosine, NBMPR
nucleoside transporter sensitivity 216
non-obese diabetic mice
initiating autoantigen (L) 331
non-ribosomal polypeptide synthetase, NRPS (L) 284
Notch
in cochlear hair cell development (L) 238
receptors, hematopoietic stem cell fate and 201
Nramp2, natural resistance-associated macrophage protein 2 431
nuclear inclusions
in CAG repeat diseases (L),(L),(L) 7, 146, 240
non-neuronal, in Huntington's disease (L) 285
nuclear medicine imaging
antisense technology for (C) 151
nuclear transfer
in human cloning (B) 423
nucleoside transporters 216
nucleotide excision repair, NER
inherited defects 86

O

obesity
agouti-related protein and melanocortins 250
animal models (D) 459
helper-dependent vectors for gene therapy 18
oestrogen *see* estrogen
oligosaccharides
in diagnostics (N) 418
oncostatin M, OSM
signaling pathway 406
organs
bioartificial (E) 1
transplantation *see* transplantation
osteogenic agents
for osteoporosis 133
osteoporosis
diagnosis and treatment 133
oxidative burst
p38 MAPK function 439
oxidative damage
in Alzheimer's disease (L) 194

P

$P2Y_2$ receptor agonist, INS365
in lung disease (N) 5
p27^{Kip1}
new class of tumor suppressor gene (L) 52
p38 MAPK signaling cascades
in inflammatory disease 439
p53 protein
in cancer (M) 334
chemical inhibitor (L) 466
chemosensitivity and (L) 508
family 387
p63 protein 387
p73 protein 387
pain
animal models (D) 319
measurement in animals (D) 319
palmoplantar keratodermas (PPK) 107
connexin defects (L) 145
pancreatic β-cells
in gene therapy of diabetes 165
transplantation 165
pancreatic islets
transplantation 165
pancreatitis
chronic 493
hereditary 493
papillomaviruses
virus-like particles *see* virus-like particles
paraoxonase, PON1
cardiovascular disease and (O) 381
parathyroid hormone-related protein, PTHrp
in bone development 481
parent-of-origin effects
in atopy 264
Parkinson's disease
human neural stem cell transplants (N) 144
overlapping pathologies/etiologies (O) 514
pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection, PANDAS (N) 6
peptides
antimicrobial, from higher eukaryotes 292
preventing brain damage (N) 282
self-assembling (M) 512
peroxidases
biology (M) 58
and human disease (M) 58
phages *see* bacteriophages
phagocytic cells
antimicrobial peptides 292
pharmacogenetics (M) 468
pharmacogenomics
cardiovascular disease (M) 195
SNPs and (N),(M) 280, 468, 538
phenylketonuria, PKU
diagnosis by tandem mass spectrometry (N) 95
Philadelphia chromosome
gene therapies targeting 359
phospholipase A_2
type-II secretory, $sPLA_2$-II, in ARDS pathogenesis (O) 244
physician scientists
declining numbers (N) 192
Pick bodies (O) 514
placenta
gene transfer to (O) 152
plants
antimicrobial peptides 292
secretion of bio-active compounds (N) 191
plaques
neuritic therapy targeting 343
in neurodegenerative diseases (O) 514
Plasmodium falciparum
circumsporozoite protein, PfCSP (N) 2
genome projects (M),(M) 11, 468
platelet-derived growth factor, PDGF
gene gun transfer, skin wounds (L) 238
polycystic kidney disease
nanobacteria in (N) 373
polyglutamine diseases *see* CAG repeat diseases
polymerase chain reaction, PCR
in bioanalysis (B) 147
clinical applications (B) 10
porcine endogenous retrovirus, PERV (M) 105
prenatal gene therapy (O) 152
prenatal screening
Down syndrome 68
presenilin 1, PS1
mutations, mechanism of action (N) 188
preterm birth
molecular basis (N) 4
prion proteins
self-assembly (M) 512
procalcitonin
as marker for sepsis (C) 286
progesterone receptors
on human sperm (L) 8
pro-opiomelanocortin, Pomc
in body weight regulation 250
prostaglandin E_2, PGE_2
in ARDS pathogenesis (O) 244
prostate cancer
new biomarkers (N) 326
protease-activated receptors, PARs
in asthma (L) 329
proteases
as gene targets 448
proteasomes
defects in tumor cells 178
inhibitor, PS-341, anti-cancer effects (N) 48
in spinocerebellar ataxia type 3, SCA3 (L) 240
protegrins 292
protein kinase C, PKC
pVHL interaction 257
proteins
aggregation inhibitors (N) 372
chip arrays (N) 326
recombinant, secretion by plant roots (N) 191
self-assembling (M) 512
sequence database (N) 420
stability, in tumors (M) 334
structural modeling (N) 325
structure determination, funding (N) 418
proteoglycans
in bone disorders 481

proteome
human (N) 420
proteomics (M) 468
protozoan parasites
genomes (M) 11
nucleoside transport 216
pseudohypoaldosteronism (N) 462
Pseudomonas aeruginosa infections
in cystic fibrosis 351
pseudovirions
human papillomavirus 209
pycnodysostosis
animal model (D) 413
pyridinyl imidazole p38 MAPK inhibitors 439

Q

Q fever vaccine
preventing type 1 diabetes (N) 143
quantitative trait locus, QTL, mapping
in alcoholism 310
in obesity (D) 459

R

radiation, ionizing
induction of cancer 157
sensitivity of hematopoietic stem cells 201
Recombinant DNA Advisory Committee, RAC
on germline gene transfer (N) 371
recombinant proteins
secretion by plant roots (N) 191
Reed—Sternberg cells
IL-13 expression (N) 463
regulatory policy
genetics (O) 198
research
extra funding in Australia (N) 328
in infectious diseases, grants for (N) 327
by physicians, decline in (N) 192
regulation of genetic (O) 198
respiratory infections
in cystic fibrosis 351
retinitis pigmentosa
model, gene therapy (L) 52
retinoblastoma
gene therapy (L) 193
retinoblastoma protein, RB
heart-specific conditional knockout mice (N) 50
retroviral vectors
chimeric 25
targeted gene delivery 448
retroviruses
porcine endogenous, PERV (M) 105
rheumatoid arthritis
animal models (D) 367
HLA association (O) 337
Rhizosecretion
bio-active compounds (N) 191
ribozymes
hepatitis C therapy 393
HIV inhibition 454
therapeutic applications (B) 242
RNA
cancer vaccines (L) 421
neuronal, oxidative damage in Alzheimer's disease (L) 194
Romano—Ward syndrome, RWS
dominant-negative effects (L) 330

S

Sandhoff disease
substrate-deprivation therapy (L) 330
scavenger receptor class B, type I, SR-BI
high-density lipoprotein receptor 518
Schistosoma
genome sequencing (M) 11
sciatica
collagen IX polymorphisms (L) 422
scleroderma
etiology 74
screening
cervical cancer (N) 189
hereditary hemochromatosis (O) 428
neonatal, using tandem mass spectrometry (N) 95
prenatal, for Down syndrome 68
self-assembling peptides
in medicine (M) 512
Semliki Forest virus, SFV
as vector (L) 146
Sendai virus *see also* hemagglutinating virus of Japan
combined with liposomes 298
SEN-V virus (N) 462
sepsis *see also* endotoxin; infections
brain iNOS expression 225
classification of patients (M) 56
complement depletion/blockade (L) 376
mediator-directed therapy (M) 56, 123
molecular pathogenesis 123
procalcitonin as serum marker (C) 286
sequence-tagged sites, STS
in SNP library construction 538
serological assays
HPV VLP vaccine responses 209
serotonin
modulation of appetite 79
shear stress, fluid
modulating endothelial phenotype 40
short stature
FGFR3 mutations causing (L),(C) 239, 336
signal transduction
in cancer (M) 334
Nef proteins (L) 422
oncostatin M pathway 406
p38 MAPK cascades 439
p53 family proteins 387
signature tagged mutagenesis, STM
bacterial virulence genes (L) 54
Sindbis virus
as vector (L) 146
single nucleotide polymorphisms, SNPs
libraries 538
pharmacogenomics and (N),(M) 280, 468, 538
whole-genome mapping (N) 419, 538
skin cancer
UV-induced 86
skin diseases
genetic, palmoplantar keratodermas 107
SNPs *see* single nucleotide polymorphisms
sodium channels
in pseudohypoaldosteronism (N) 462
sodium chloride, NaCl
airway regulation (L) 329
somagenic neurodegeneration (O) 470
Sp1
pVHL interaction 257
sperm
progesterone and GABA receptors (L) 8
spinal muscular atrophy
SMN protein (L) 98
spinocerebellar ataxia
novel form, SCA8 (L) 240
type 1, SCA1, role of nuclear inclusions (L) 7
type 3, SCA3, role of proteasomes (L) 240
split-hand/split-foot malformation, SHFM
genetics (L) 507
SR-BI, scavenger receptor class B, type I
high-density lipoprotein receptor 518
Staphylococcus aureus
airway infections in cystic fibrosis 351
location-dependent virulence mechanisms (L) 54
vaccines (L) 331, 532
stem cells
hematopoietic *see* hematopoietic stem cells
human embryonic (E),(N),(M) 1, 47, 105
in utero transplantation (O) 288
neural *see* neural progenitor, stem, cells
stop codons, premature
suppression by gentamicin (N) 461
streptococcal infections
in Tourette's syndrome (N) 6
streptococci
invasive mechanisms (L) 193
Streptococcus pneumoniae
location-dependent virulence mechanisms (L) 54
stress
preterm birth and (N) 4
response, heat shock proteins 525
subunit vaccines
tuberculosis 487
surface enhanced laser desorption/ionization, SELDI,
spectroscopy (N) 326
surfactant, pulmonary
changes in ARDS (O) 244

surfactant protein A, SP-A
in ARDS pathogenesis (O) 244
survival motor neuron, SMN, protein
in spinal muscular atrophy (L) 98
Sydenham's chorea (N) 6
synuclein-containing inclusions
in neurodegenerative diseases (O) 514
systemic inflammatory response syndrome, SIRS 123
systemic lupus erythematosus, SLE
genetic factors (N) 504
systemic sclerosis
etiology 74

T

tandem mass spectrometry
diagnosis of inborn errors of metabolism (N) 95
tau protein
in neurodegenerative diseases (O) 514
T-cell receptors, TCR
in tumor cell recognition 178
variants, in asthma and atopy 264
telomerase
and cancer 114
thalassemia
prenatal gene therapy (O) 152
thyroid peroxidase, TPO (M) 58
tissue engineering
methods and protocols (B) 333
tolerance, immunological
to adenoviral vectors, inducing (L) 53
donor specific, gene therapy inducing 400
Tourette's syndrome
role of streptococcal autoantibodies (N) 6
TP53 gene
family of proteins 387
product *see* p53 protein
transcription factor decoy oligonucleotides, TFOs
in chronic myelogenous leukemia 359
transcription factors
hematopoietic, in leukemia (M) 510
trans-dominant proteins
HIV inhibition 454
transferrin
function 431
saturation, TS, screening (O) 428
transformation
normal human cells (M) 510
transforming growth factor beta TGF-β, gene variations
and essential hypertension (N) 431
transfusion
destruction of viruses in blood for (N) 49
transgenic mice
alcoholism studies 310
Alzheimer's disease models (D) 274
Down syndrome models (D) 276
familial hypertrophic cardiomyopathy models (D) 544
heat shock protein 70 overexpressing 525
transgenic plants
secretion of recombinant proteins (N) 191
translocations, chromosomal
in leukemia (M) 510
transplantation *see also* xenotransplantation
gene therapy to facilitate 400
human embryonic stem cells (E),(N),(M) 1, 47, 105
human neural stem cells (N) 144
in neurodegenerative diseases 474
pancreatic islets 165
stem cells *in utero* (O) 288
transporter associated with antigen processing, TAP
downregulation in cancer 178
Trends Online website (E) 187
trichostatin A
in breast cancer (N) 503
trichothiodystrophy, TTD
defective DNA repair 86
trisomy 21 *see* Down syndrome
Trojan horse
anti-HIV strategy 454
Trypanosoma
genome sequencing (M) 11
nucleoside transport 216
trypsinogen, cationic
gene defects in chronic pancreatitis 493
tuberculosis, TB
vaccine *see* bacille Calmette-Guérin, BCG, vaccine
tumor cells
inhibition by oncostatin M 406
recognition by CTLs and NK cells 178
tumorigenesis
E-cadherin downregulation in 172
reversible, by *Myc* (L) 466
role of gelsolin (N) 503
tumor necrosis factor α, TNF-α
in ARDS pathogenesis (O) 244
IGF-I interaction in CNS (L) 466
inhibition in sepsis (M) 56
polymorphisms, in asthma 264
tumor necrosis factor-related apoptosis ligand, TRAIL
anti-cancer activity (N) 374
tumors *see also* cancer
endometriosis analogy 304
immune surveillance *see* immune surveillance, tumors
tumor suppressor genes
ATM and *NBS1* genes 157
DNA methylation (L) 465
EXT 481
$p27^{Kip1}$ (L) 52
TP53 family 387
VHL 257

U

ubiquitination
defect in DiGeorge syndrome (N) 233
role of pVHL 257
ultraviolet, UV, light
induced DNA damage 86
urease
Helicobacter pylori 32
urinary analytes
prenatal screening for Down syndrome 68
urinary tract infections, UTI
role of lipopolysaccharide (L) 507
urotensin II (L) 466

V

vaccines
BCG (L) 331, 487
cervical cancer 209
cholesteryl ester transfer protein 281
DNA *see* DNA, vaccines
Helicobacter pylori 32
HIV (N) 97, 141
mucosal, CTL responses (L) 145
Q fever, and type 1 diabetes (N) 143
RNA cancer (L) 421
Staphylococcus aureus (L) 331, 532
vacuolating cytotoxin, VacA
Helicobacter pylori 32
vascular endothelium
blood flow modulating gene expression 40
regulation of leukocyte extravasation (O) 61
vasculitis
antiperoxidase antibodies and (M) 58
VBP-1, VHL-binding protein 257
vectors
arthritis gene therapy (M) 148
gene targeting 448
gene therapy (B) 424
HIV gene therapy 454
hybrid, HVJ-liposomes 298
inadvertent germline gene transfer (N) 371
for knockout mice generation (L) 375
non-viral, structure and design (M) 241
prenatal gene therapy (O) 152
viral *see* viral vectors
vertebrates
antimicrobial peptides 292
VHL gene product, pVHL 257
Vibrio cholerae
bacteriophage-encoded genes (L) 329
VIRADAPT trial
HIV genotyping (N) 417
viral hepatitis (M) 425
viral vectors
adenoviral *see* adenoviral vectors
alphaviruses as (L) 146
chimeric 25
HPV virus-like particles, VLPs (L) 8
targeted gene delivery 448

virulence factors
extracellular matrix-binding proteins, ECMBPs, as 532
Helicobacter pylori 32
virulence genes
bacteriophage encoded (L) 329
location dependence (L) 54
viruses
destruction in blood for transfusion (N) 49
genotyping (N) 417
molecular biology (B) 55
new hepatitis (N) 462
oncogenic, HLA-associated susceptibility (O) 337
ribozyme-mediated inhibition (B) 242
xenotransplantation risks (B) 377
virus-like particles, VLPs
characterization 209
as tools for study of HPV (L) 8
vaccines for cervical cancer 209
vitamin E
formation of atherosclerosis and (L) 8
von Hippel–Lindau, VHL, disease 257

W

wasting disorders
role of neuropeptide Y 79
websites
Trends Online (E) 187
weight, body
disorders, lipodystrophies (N) 328
regulation, role of agouti-related protein 250, 336
Whitaker Foundation (N) 3
wound healing
particle-mediated PDGF gene transfer (L) 238

X

xenotransplantation
cell therapy and (M) 105
gene therapy and 400
New York workshop proceedings (B) 377
xeroderma pigmentosum, XP 86